e-learning
resources
Amsterdam 2015
Tuesday, 29.09.2015
Lung cancer: prognostic factors and features of oncogene-driven tumours
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
p16(ink4) expression and spirometry tests have similar survival outcomes values in non-small-cell lung cancer patients
Edin Jusufovic (Tuzla, Bosnia and Herzegovina), Rifat Sejdinovic, Edin Jusufovic, Dragan Keser, Besim Prnjavorac, Ljiljana Sejdinovic, Azra Okanovic
Source:
International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours
Session:
Lung cancer: prognostic factors and features of oncogene-driven tumours
Session type:
Thematic Poster Session
Number:
4243
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Edin Jusufovic (Tuzla, Bosnia and Herzegovina), Rifat Sejdinovic, Edin Jusufovic, Dragan Keser, Besim Prnjavorac, Ljiljana Sejdinovic, Azra Okanovic. p16(ink4) expression and spirometry tests have similar survival outcomes values in non-small-cell lung cancer patients. Eur Respir J 2015; 46: Suppl. 59, 4243
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight
N3 hilar sampling decision in the staging of mediastinal lung cancer
Related content which might interest you:
Possible predictors of the bronchodilation test response within lung function assessment of patients with operable lung cancer
Source: Eur Respir J 2005; 26: Suppl. 49, 326s
Year: 2005
Lung function testing for the preoperative evaluation of patients with lung cancer
Source: Annual Congress 2003 - Lung function testing for preoperative evaluation in lung cancer patients
Year: 2003
Comparing exhaled molecular profiles of patients with non-small cell lung cancer (NSCLC) with those of patients with non-pulmonary malignancy
Source: Annual Congress 2010 - Exhaled biomarkers: smells like disease
Year: 2010
Does the lung function affect the survival time in patients with resected non-small cell lung cancer?
Source: Annual Congress 2007 - Lung function parameters before and after thoracic surgery
Year: 2007
Pulmonary function testing in patients with lung cancer
Source: Annual Congress 2012 - Instructive clinical aspects of thoracic oncology
Year: 2012
Cardiopulmonary exercise testing in patients with non-small cell lung cancer: maximality criteria analysis.
Source: Virtual Congress 2020 – Localised non-small cell lung cancer
Year: 2020
The evaluation of lung cancer patients
Source: Eur Respir J 2005; 26: Suppl. 49, 323s
Year: 2005
Factors associated with delayed recovery to predicted FEV1 calculated with perfusion scan in non-small-cell lung cancer patients after lobectomy
Source: International Congress 2017 – Lung cancer: important scientific reports from endoscopists and thoracic surgeons
Year: 2017
Utility of the 3-minute chair rise test (3CRT) to assess cardiopulmonary fitness of patients with non-small cell lung cancer before lung resection.
Source: Virtual Congress 2020 – Thoracic surgery: developments in diagnostics and outcomes
Year: 2020
Differences in the pattern of FEV1 and VC change after lung resection between lung cancer patients with limited and normal lung function
Source: Eur Respir J 2006; 28: Suppl. 50, 278s
Year: 2006
The utility of vibration response imaging for calculation of ppoFEV1 and ppoD
L,CO
in patients with lung cancer referred for resection – The influence of coexisting COPD
Source: Annual Congress 2013 –Lung surgery: preoperative assessment and postoperative outcome
Year: 2013
Correlation of quality of life parameters with parameters of health state in patients with nonsmall cell lung cancer treated by chemotherapy
Source: Eur Respir J 2003; 22: Suppl. 45, 30s
Year: 2003
Comparison of two methods for estimating the predicted postoperative (PPO) lung function after lung cancer resection in COPD patients
Source: Annual Congress 2009 - Preoperative functional assessment and surgery for malignant diseases
Year: 2009
Changes in lung function tests in lung carcinoma patients due to radiotherapy
Source: Eur Respir J 2001; 18: Suppl. 33, 221s
Year: 2001
Chemotherapy improves low performance status lung cancer patients
Source: Eur Respir J 2007; 30: 1186-1192
Year: 2007
Three-year spirometric evolution after lobectomy in lung cancer patients with or without COPD previous surgery
Source: International Congress 2016 – Clinical aspects of lung cancer
Year: 2016
Estimated postoperative pulmonary function and 6 months recovery for lobectomized lung cancer patients with and without COPD
Source: International Congress 2016 – Surgical strategy for complex diseases
Year: 2016
Lung function estimation in patients with lung cancer qualified for surgical treatment
Source: Eur Respir J 2006; 28: Suppl. 50, 719s
Year: 2006
Lung function assessment in octogenarians with lung cancer diagnosis
Source: International Congress 2017 – Thoracic surgery
Year: 2017
Treatment of patients with advanced non-small-cell lung cancer (NSCLC) with erlotinib: results from clinical practice
Source: Annual Congress 2008 - Therapy of thoracic tumours
Year: 2008
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept